Condition: End Stage Renal Disease · Sponsor: Iperboreal Pharma Srl
Randomized, controlled, parallel groups, open-label, blinded end-point assessment, multicenter study, comparing the effects of a low glucose peritoneal dialysis solution, XyloCore, to glucose solutions (Physioneal, Fixioneal, Dianeal, Balance, Bicavera, Bicanova or Equibalance) only regimen, in patients with End-Stage Renal Disease (ESRD) receiving Continuous Ambulatory Peritoneal Dialysis (CAPD), over a 6-month study period.
This description comes directly from the study's public registry record.
Arduino Arduini, MD · +39.333.6409595 · a.arduini@iperboreal.com
Always discuss trial participation with your own doctor first.
| Aalborg University | Aalborg, Denmark | Not Yet Recruiting |
| Aarhus University Hospital | Aarhus, Denmark | Recruiting |
| Zealand University Hospital | Roskilde, Denmark | Recruiting |
| Dialysis Center DaVita | Düsseldorf, Germany | Recruiting |
| Ospedale Madonna del Soccorso | Ascoli Piceno, Italy | Recruiting |
| Ospedale Santa Maria Annunziata | Bagno a Ripoli, Italy | Not Yet Recruiting |
| Azienda Universitaria Ospedaliera di Bari | Bari, Italy | Recruiting |
| ASST Spedali Civili di Brescia | Brescia, Italy | Not Yet Recruiting |
| Ospedale SS. Annunziata | Chieti, Italy | Recruiting |
| IRCCS Policlinico San Martino | Genova, Italy | Not Yet Recruiting |
| Ospedale Civile San Salvatore | L’Aquila, Italy | Recruiting |
| ASST Fatebenefratelli-Sacco -Ospedale Luigi Sacco | Milan, Italy | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03994471